Natco Pharma Ltd
NSE:NATCOPHARM
Natco Pharma Ltd
Selling, General & Administrative
Natco Pharma Ltd
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Natco Pharma Ltd
NSE:NATCOPHARM
|
Selling, General & Administrative
-₹5.8B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-16%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Selling, General & Administrative
-₹136.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Selling, General & Administrative
-₹46.8B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-10%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Selling, General & Administrative
-₹98.5B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-10%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Selling, General & Administrative
-₹21.3B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-10%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Selling, General & Administrative
-₹33.1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Natco Pharma Ltd
Glance View
Nestled in the bustling business corridors of Hyderabad, India, Natco Pharma Ltd. has cultivated a strong presence in the pharmaceutical industry over the decades. Founded in 1981, the company initially ventured into the local market, gradually establishing itself as a critical player through specialization in complex chemistry and niche therapeutic sectors. The company's primary focus is on the development and manufacturing of generic drugs, specifically in the oncology and neurology segments. In these high-stakes areas, Natco leverages its robust research and development capabilities to produce affordable alternatives to expensive branded medications, thereby ensuring access to critical treatments for broader populations. Natco Pharma's business acumen extends beyond merely producing generics. It is adept at capitalizing on patent expirations, quickly launching generics and biosimilars in both domestic and international markets. The company has strategically focused operations in markets such as the United States and Europe, where it partners with local distributors to reach end-users. Through a combination of manufacturing efficiencies and strategic partnerships, Natco is able to maintain competitive pricing, thus enhancing its market penetration and revenue generation. Its integrated business model, combining in-house R&D, manufacturing, and distribution, ensures that Natco remains a formidable player, bridging the gap between complex pharmaceuticals and cost-effective healthcare solutions.
See Also
What is Natco Pharma Ltd's Selling, General & Administrative?
Selling, General & Administrative
-5.8B
INR
Based on the financial report for Dec 31, 2024, Natco Pharma Ltd's Selling, General & Administrative amounts to -5.8B INR.
What is Natco Pharma Ltd's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-16%
Over the last year, the Selling, General & Administrative growth was -15%. The average annual Selling, General & Administrative growth rates for Natco Pharma Ltd have been -10% over the past three years , -9% over the past five years , and -16% over the past ten years .
You don't have any saved screeners yet